A multifunctional drug delivery system（GNRs@mSiO_2-HA-RGD） was developed by conjugating targeting ligand hyaluronic acid（HA） and RGD with mesoporous silica-coated gold nanorods（GNRs@mSiO_2） for dual-targeted che...A multifunctional drug delivery system（GNRs@mSiO_2-HA-RGD） was developed by conjugating targeting ligand hyaluronic acid（HA） and RGD with mesoporous silica-coated gold nanorods（GNRs@mSiO_2） for dual-targeted chemo-photothermal therapy. The physiochemical properties of the prepared nanoparticles were characterized by FTIR, UV-vis spectra, and ~1H NMR. Doxorubicin hydrochloride（DOX）, an anticancer drug, was used as the model drug to investigate the drug loading, in vitro drug release profiles and cytotoxicity. The experimental results show that DOX-GNRs@mSiO_2-HA-RGD is synthesized with a mean diameter of 116 nm and a sufficient load capacity of about 19.8%. It also has p H-enzyme sensitive and NIRtriggered drug release manner. Cellular uptake indicates that DOX-GNRs@mSiO_2-HA-RGD exhibits a higher cellular uptake via CD44 receptor and integrin receptor mediated endocytosis compared with the GNRs@mSiO_2 modified with one receptor or no receptor. In comparison with chemotherapy or photothermal therapy alone, DOX-GNRs@mSiO_2-HA-RGD displayes the synergistic effects and achieves a higher therapeutic efficacy. It can be expected that DOX-GNRs@mSiO_2-HA-RGD is a potential dual-targeted chemo-photothermal therapeutic platform for effective cancer treatment.展开更多
基金Funded by the National Natural Science Foundation of China(Nos.51473130 and 51572206)the Wuhan Huanghe excellence plan and Entrepreneurship Training Program of Wuhan University and Technology(Nos.20171049720018,20171049720019,and 20171049720009)
文摘A multifunctional drug delivery system（GNRs@mSiO_2-HA-RGD） was developed by conjugating targeting ligand hyaluronic acid（HA） and RGD with mesoporous silica-coated gold nanorods（GNRs@mSiO_2） for dual-targeted chemo-photothermal therapy. The physiochemical properties of the prepared nanoparticles were characterized by FTIR, UV-vis spectra, and ~1H NMR. Doxorubicin hydrochloride（DOX）, an anticancer drug, was used as the model drug to investigate the drug loading, in vitro drug release profiles and cytotoxicity. The experimental results show that DOX-GNRs@mSiO_2-HA-RGD is synthesized with a mean diameter of 116 nm and a sufficient load capacity of about 19.8%. It also has p H-enzyme sensitive and NIRtriggered drug release manner. Cellular uptake indicates that DOX-GNRs@mSiO_2-HA-RGD exhibits a higher cellular uptake via CD44 receptor and integrin receptor mediated endocytosis compared with the GNRs@mSiO_2 modified with one receptor or no receptor. In comparison with chemotherapy or photothermal therapy alone, DOX-GNRs@mSiO_2-HA-RGD displayes the synergistic effects and achieves a higher therapeutic efficacy. It can be expected that DOX-GNRs@mSiO_2-HA-RGD is a potential dual-targeted chemo-photothermal therapeutic platform for effective cancer treatment.
